RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 CONFIRM-HF: Novel Approach Treating ID Improved Function, Symptoms, and QOL
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 27
SP 14
OP 15
DO 10.1177/155989771427007
UL http://mdc.sagepub.com/content/14/27/14.abstract
AB A sustainable improvement in functional capacity, symptoms, and quality of life was shown in patients with symptomatic chronic heart failure (HF) and iron deficiency (ID) who were treated with intravenous (IV) ferric carboxymaltose (FCM) throughout 1 year, and this treatment may reduce the risk of hospitalizations due to worsening HF. This article presents the results of A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency [CONFIRM-HF; Ponikowski P et al. Eur Heart J. 2014].